Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mariangela Ciccarese et al.|The Breast|2018Cited by 35
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective studyGrazia Arpino, Sabino De Placido, Andrea Michelotti et al.|Journal of Cancer Research and Clinical Oncology|2015Cited by 15
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|ESMO Open|2021Cited by 12
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).Valentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2020Cited by 3
Eribulin in combination with bevacizumab as second-line treatment for HER2–negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|Research Square|2020Cited by 1